Pardes Biosciences initially received funding from Foresite Capital Management, Khosla Ventures and GMF Capital.
They have been approved for other illnesses including HIV and hepatitis C. Proteases are key to viral growth, and inhibitors block the virus’ ability to set up a replication factory in the body. It reduced the risk of hospitalization and death by 30% in early studies, according to reports. Meanwhile, Merck’s molnupiravir pill, developed with partner Ridgeback Biotherapeutics, uses a different approach, called nucleoside analog, and isn’t allowed for pregnant women or children. Henson said early research suggests Pardes Biosciences’ experimental drug may have the potential to be a stand-alone without requiring a companion booster pill, though it’s too soon to know. But it needs to be taken along with an oral generic booster drug called ritonavir, which can cause gastrointestinal side effects and potentially interferes with certain existing medications. It reduced the risk of hospitalization and death for mild to moderate COVID-19 patients by 88% in studies.
Pfizer’s oral treatment, Paxlovid, also is a protease inhibitor. Still, Henson contends the race is far from over. Pardes probably wouldn’t apply for emergency authorization until late next year, at the earliest. Pharmaceutical giants Pfizer and Merck last week received emergency-use authorization from federal regulators for pills to treat the virus. Pardes Biosciences is a bit of a dark horse in the race for a COVID-19 pill. Ideally, you are on medication within 24 hours of diagnosis.” The results get sent to your doctor and your doctor calls in a prescription that’s delivered to your house, and you never leave. “I think the future is moving toward a telehealth system where you have symptoms, you take a home test - which are already available.
“The world needs some sort of pill that you can take at home,” Heidi Henson, Pardes Biosciences’ chief financial officer, said in an interview. It aims to offer initial treatment for people with the virus - potentially sidetracking serious illness and keeping them out of overwhelmed hospitals. Carlsbad startup Pardes Biosciences, which has begun clinical trials for an experimental pill to treat COVID-19, has raised $199 million through a special purpose acquisition company, or SPAC.įounded in February 2020 specifically to fight the pandemic, the company is pursuing a protease inhibitor antiviral compound called PBI-0451.
0 kommentar(er)
